Skip to main content
Log in

Efficient production of the anti-aging drug Cycloastragenol: insight from two Glycosidases by enzyme mining

  • Biotechnological products and process engineering
  • Published:
Applied Microbiology and Biotechnology Aims and scope Submit manuscript

Abstract

The telomerase activator cycloastragenol (CA) is regarded as a potential anti-aging drug with promising applications in the food and medical industry. However, one remaining challenge is the low efficiency of CA production. Herein, we developed an enzyme-based approach by applying two enzymes (β-xylosidase: Xyl-T; β-glucosidase: Bgcm) for efficient CA production. Both key glycosidases, mined by activity tracking or homology sequence screening, were successfully over-expressed and showed prominent enzymatic activity profiles, including widely pH stability (Xyl-T: pH 3.0–8.0; Bgcm: pH 4.0–10.0), high catalytic efficiency (kcat/Km: 0.096 mM-1s−1 (Xyl-T) and 3.08 mM-1s−1 (Bgcm)), and mesophilic optimum catalytic temperature (50 °C). Besides, the putative catalytic residues (Xyl-T: Asp311/Glu 521; Bgcm: Asp311/Glu 521) and the potential substrate-binding mechanism of Xyl-T and Bgcm were predicted by comprehensive computational analysis, providing valuable insight into the hydrolysis of substrates at the molecular level. Notably, a rationally designed two-step reaction process was introduced to improve the CA yield and increased up to 96.5% in the gram-scale production, providing a potential alternative for the industrial CA bio-production. In essence, the explored enzymes, the developed enzyme-based approach, and the obtained knowledge from catalytic mechanisms empower researchers to further engineer the CA production and might be applied for other chemicals synthesis.

Key points

• A β-xylosidase and a β-glucosidase were mined to hydrolyze ASI into CA.

• The two recombinant glycosidases showed prominent catalytic profiles.

• Two-step enzymatic catalysis for CA production from ASI was developed.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig.5
Fig. 6
Fig. 7.

Similar content being viewed by others

References

Download references

Acknowledgment

We thank the instrument support from Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.

Funding

This study was funded by the National Key Research Development Program [Grant No. 2016YFD0400601].

Author information

Authors and Affiliations

Authors

Contributions

Yuan Q and Wang W conceived and designed research. Cheng L and Zhang H conducted experiments and computational analysis. Cheng L analyzed data and wrote the manuscript. Wang W and Cui H improved the manuscript. All authors read and approved the manuscript.

Corresponding authors

Correspondence to Wenya Wang or Qipeng Yuan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 4833 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, L., Zhang, H., Cui, H. et al. Efficient production of the anti-aging drug Cycloastragenol: insight from two Glycosidases by enzyme mining. Appl Microbiol Biotechnol 104, 9991–10004 (2020). https://doi.org/10.1007/s00253-020-10966-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00253-020-10966-5

Keywords

Navigation